Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANVS NASDAQ:ENTX NASDAQ:ME NASDAQ:PDSB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$1.89-5.3%$2.02$1.54▼$5.50$68.95M1.271.25 million shs1.40 million shsENTXEntera Bio$1.18-3.3%$1.21$0.91▼$3.22$60.13M1.5683,337 shs60,296 shsME23andMe$0.61$0.50$0.53▼$9.57$16.27M1.191.57 million shsN/APDSBPDS Biotechnology$1.02-16.4%$1.05$0.51▼$1.92$68.10M1.571.17 million shs1.61 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio-4.56%-2.08%-21.29%-24.30%-41.64%ENTXEntera Bio-2.48%-12.59%-5.60%-5.60%-42.44%ME23andMe0.00%0.00%0.00%0.00%+21.75%PDSBPDS Biotechnology-16.39%-5.56%-3.77%+51.58%-38.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$1.89-5.3%$2.02$1.54▼$5.50$68.95M1.271.25 million shs1.40 million shsENTXEntera Bio$1.18-3.3%$1.21$0.91▼$3.22$60.13M1.5683,337 shs60,296 shsME23andMe$0.61$0.50$0.53▼$9.57$16.27M1.191.57 million shsN/APDSBPDS Biotechnology$1.02-16.4%$1.05$0.51▼$1.92$68.10M1.571.17 million shs1.61 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio-4.56%-2.08%-21.29%-24.30%-41.64%ENTXEntera Bio-2.48%-12.59%-5.60%-5.60%-42.44%ME23andMe0.00%0.00%0.00%0.00%+21.75%PDSBPDS Biotechnology-16.39%-5.56%-3.77%+51.58%-38.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio 2.25Hold$13.50616.18% UpsideENTXEntera Bio 2.00Hold$9.00662.71% UpsideME23andMe 0.00N/AN/AN/APDSBPDS Biotechnology 2.33Hold$9.00782.35% UpsideCurrent Analyst Ratings BreakdownLatest ME, PDSB, ANVS, and ENTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026ANVSAnnovis Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026ENTXEntera Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $9.004/21/2026ENTXEntera Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PDSBPDS Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/15/2026PDSBPDS Biotechnology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.004/14/2026ANVSAnnovis Bio Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.00(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A$0.64 per shareN/AENTXEntera Bio$40K1,454.06N/AN/A$0.29 per share4.07ME23andMe$208.78M0.08$0.65 per share0.93$2.34 per share0.26PDSBPDS BiotechnologyN/AN/AN/AN/A$0.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$28.85M-$1.71N/AN/AN/AN/A-318.08%-215.47%8/18/2026 (Estimated)ENTXEntera Bio-$11.44M-$0.27N/AN/AN/AN/A-83.31%-70.83%8/14/2026 (Estimated)ME23andMe-$666.70M-$15.45N/AN/AN/A-183.39%-170.07%-62.13%N/APDSBPDS Biotechnology-$34.50M-$0.67N/AN/AN/AN/A-346.02%-102.36%8/12/2026 (Estimated)Latest ME, PDSB, ANVS, and ENTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026ANVSAnnovis Bio-$0.3950-$0.63-$0.2350-$0.63N/AN/A5/13/2026Q1 2026PDSBPDS Biotechnology-$0.15-$0.13+$0.02-$0.13N/AN/A5/8/2026Q1 2026ENTXEntera Bio-$0.08-$0.07+$0.01$0.07N/AN/A3/30/2026Q4 2025PDSBPDS Biotechnology-$0.20-$0.14+$0.06-$0.14N/AN/A3/27/2026Q4 2025ENTXEntera Bio-$0.09-$0.07+$0.02$0.07N/AN/A3/13/2026Q4 2025ANVSAnnovis Bio-$0.3084-$0.39-$0.0816-$0.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A1.271.27ENTXEntera BioN/A7.937.93ME23andMeN/A1.050.91PDSBPDS Biotechnology2.732.262.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%ENTXEntera Bio14.11%ME23andMe36.10%PDSBPDS Biotechnology26.84%Insider OwnershipCompanyInsider OwnershipANVSAnnovis Bio20.80%ENTXEntera Bio10.38%ME23andMe26.32%PDSBPDS Biotechnology9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio334.65 million27.44 millionOptionableENTXEntera Bio2049.29 million44.12 millionOptionableME23andMe77026.83 million19.77 millionNot OptionablePDSBPDS Biotechnology2055.82 million50.68 millionOptionableME, PDSB, ANVS, and ENTX HeadlinesRecent News About These CompaniesCritical Comparison: PDS Biotechnology (NASDAQ:PDSB) & Pharming Group (NASDAQ:PHAR)May 27, 2026 | americanbankingnews.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2026 Earnings Call TranscriptMay 15, 2026 | insidermonkey.comPDS Biotechnology Q1 2026 Earnings Call: Complete TranscriptMay 15, 2026 | finance.yahoo.comPDS Biotechnology Corp (PDSB) Q1 2026 Earnings Call Highlights: Strategic Advancements and ...May 15, 2026 | finance.yahoo.comPDS Biotechnology Q1 Earnings Call HighlightsMay 13, 2026 | marketbeat.comPDS Biotechnology Corporation Schedules Investor Webcast for Business and Clinical UpdateMay 13, 2026 | quiverquant.comQPDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate UpdateMay 13, 2026 | markets.businessinsider.comPDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate UpdateMay 13, 2026 | globenewswire.comPDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial ResultsMay 6, 2026 | globenewswire.comPDS Biotechnology Corp.April 22, 2026 | barrons.comB. Riley Securities Sticks to Their Buy Rating for PDS Biotechnology (PDSB)April 17, 2026 | theglobeandmail.comPDSB stock hits 37-week high — here’s the latest on its therapy to treat metastatic colorectal cancerApril 15, 2026 | msn.comPDS Biotechnology Announces Promising Phase 2 Trial Results of PDS01ADC for Treatment of Colorectal Liver MetastasesApril 15, 2026 | quiverquant.comQPDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) TrialApril 15, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Eli Lilly & Co (LLY) and Praxis Precision Medicines (PRAX)April 7, 2026 | theglobeandmail.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 earnings call transcriptApril 1, 2026 | msn.comPDS Biotechnology Corp (PDSB) Q4 2025 Earnings Call Highlights: Financial Discipline Amid ...March 31, 2026 | finance.yahoo.comPDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call TranscriptMarch 30, 2026 | seekingalpha.comPDS Biotechnology: Q4 Earnings SnapshotMarch 30, 2026 | finance.yahoo.comPDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical AdvancementMarch 30, 2026 | globenewswire.comPDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial ResultsMarch 24, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBefore the Moon Base Gets Built, These 4 Companies WinBy Thomas Hughes | May 11, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 20263 Rare Earth Stocks That Win No Matter What China Does NextBy Bridget Bennett | May 24, 2026ME, PDSB, ANVS, and ENTX Company DescriptionsAnnovis Bio NYSE:ANVS$1.88 -0.11 (-5.28%) Closing price 06/5/2026 03:59 PM EasternExtended Trading$1.88 0.00 (0.00%) As of 06/5/2026 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Entera Bio NASDAQ:ENTX$1.18 -0.04 (-3.28%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.18 0.00 (0.00%) As of 06/5/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.23andMe NASDAQ:ME23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.PDS Biotechnology NASDAQ:PDSB$1.02 -0.20 (-16.39%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.08 +0.06 (+5.88%) As of 06/5/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
